Objective: To investigate whether pathogenic melanocortin-4 receptor (MC4R) mutations are a common cause of obesity in Belgium. Design: Cross-sectional mutation analysis. Subjects: In total, 95 morbidly obese adults (mean age 44.02711.35 years; mean BMI 47.8774.17 kg/m 2 ) and 123 obese children and adolescents were screened for mutations in MC4R (mean age 16.5672.58 years; BMI495th percentile for age and sex; mean % overweight 170.86723.63). Measurements: A series of anthropometric (e.g. weight, height, waist, hip), biochemical and clinical measurements were performed on all subjects. The entire coding region of MC4R was screened using DHPLC, a highly sensitive and specific method for mutation analysis. Direct sequencing was performed when the chromatogram deviated from the WT pattern. Results: Mutation screening of a cohort of Belgian obese adults and children did not detect any pathogenic mutations as only the previously described polymorphisms Val103Ile, Thr112Met and Ile251Leu were detected. Conclusion: Pathogenic mutations in MC4R are not a common cause of obesity in a Belgian population of obese adults, children and adolescents.
Introduction
Obesity is one of the major health problems in industrialized countries. In most cases, the phenotype is the result of the interaction between environmental and several genetic factors. However, in a minority of cases obesity has been associated with a mutation in one gene. Currently, six such monogenic forms of obesity have been described. They include mutations in the genes encoding leptin, leptin receptor, proconvertase 1, pro-opiomelanocortin (POMC), the transcription factor SIM1 and melanocortin-4 receptor (MC4R). 1 MC4R is a seven transmembrane G-protein-coupled receptor, which is highly expressed in the hypothalamus, a brain region involved in food intake regulation. 2 The receptor is activated by a-melanocyte-stimulating hormone (a-MSH), a cleavage product of POMC, while Agouti-related peptide (AGRP) acts as an antagonist. 3 The hormone leptin stimulates POMC neurons, resulting in the release of a-MSH which binds on the MC4R. This leads to activation of an adenylate cyclase signaling pathway, which generates an anorexigenic signal. Leptin also inhibits the orexigenic neurons expressing neuropeptide Y (NPY) and AGRP. 2, 4, 5 The importance of MC4R in the etiology of obesity was first demonstrated through the inactivation of this receptor in mice. Mice lacking the receptor develop a maturity-onset obesity syndrome associated with hyperphagia, hyperinsulinemia and hyperglycemia. 6 In 1998, two groups reported the first mutations in MC4R in humans resulting in a nonfunctional receptor. Patients carrying these mutations, all developed severe early-onset obesity. 7, 8 Since then several groups have reported sequence variants in MC4R in different populations. There is a large variation in the frequency of mutations between different studies ranging from 0% mutations 9-11 to 6.3%. 12 This clearly depends on the ethnic background of the population and the phenotypical characteristics of the cohort studied. Recently, Larsen et al.
13
published a very comprehensive study on MC4R mutations in which they screened 750 obese Danish army recruits and 706 controls. The size of this study and the fact that it is based on an unselected population-based cohort make it a good standard. In this study, the authors found a frequency of pathogenic MC4R mutations of 2.5%, which we can now consider to be one of the best estimates of MC4R mutation prevalence in the obese population. Most reported MC4R mutations are missense mutations resulting in loss of function due to reduced ligand binding, reduced intracellular activity or reduced cell surface expression. However, two pathogenic mutations (Leu250Gln and Pro230Leu) were found to induce constitutive activity of the receptor. 14, 15 Frameshift mutations, such as the originally described 4-bp insertion 7 and 4-bp deletion, 8 cause severe obesity due to haploinsufficiency.
In the present study, we wanted to evaluate the role of MCR4 in a Belgian population of obese children and adults. All subjects were recruited from patients consulting the outpatient obesity clinic at the University Hospital. At enrolment none were involved in an ongoing weight management program. Patients with known diabetes were excluded from the study. All subjects were of Caucasian descent. An extended series of anthropometric (height, weight, BMI, waist, hip, WHR, skinfold thickness, etc.), biochemical (plasma leptin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose and insulin levels during oral glucose tolerance test, etc.), hematological and clinical measurements (smoking behavior, alcohol intake) were performed on all subjects. Unfortunately, no information was available on age of onset of obesity and eating behavior. Written informed consent was obtained from all participants and the study was approved by the local ethics committee.
Materials and methods
The MC4R gene was amplified by PCR on genomic DNA isolated from whole blood. Mutation screening was performed using the WAVE Nucleic Acid Fragment Analysis System (Transgenomic Inc., Crewe, UK). This system uses denaturing high-performance liquid chromatography (DHPLC), a highly sensitive method for detecting new mutations. 16, 17 The coding region of MC4R (999 bp) was divided into three amplicons for DHPLC screening, and melting temperatures for optimal separation of homo-and heteroduplexes were deduced from the melting profile of each amplicon using WAVE Navigator software (Transgenomic Inc., Crewe, UK). For each amplicon, PCR was performed using Optimase and appropriate buffers (Transgenomic Inc., Crewe, UK) under standard conditions, with 30 cycles of 941C for 1 min, 591C for 1 min and 721C for 1 min. Primers are available on request. After subsequent denaturation and reannealing, 5 ml of denaturated-renaturated PCR product was loaded onto a preheated column in a WAVE Nucleic Acid Fragment Analysis System (Transgenomic Inc., Crewe, UK). PCR amplicons with more than one peak or differences from wild type in peak appearance were sequenced to confirm putative sequence variations. Sequencing was performed using the PCR primers, and fragments were analyzed on an ABI 3100 Genetic Analyzer (Applied Biosystems Inc., Foster City, CA, USA).
Comparison of polymorphism frequency between cases and controls was performed using a chi square test with SPSS (version 12.0, SPSS Inc., Chicago, IL, USA).
Results
Of the 218 subjects screened for mutations in MC4R, only those with aberrant chromatograms were sequenced. DHPLC screening of the 95 adults identified four sequence variants of MC4R (frequency ¼ 4.21%). Three adults were heterozygous for the Val103Ile variant and one for the Thr112Met variant, two previously reported polymorphisms. 9, 18 Neither the third known polymorphism, Ile251Leu, 19 nor MC4R analysis in Belgian obese children and adults S Beckers et al pathogenic mutations in MC4R were found in our cohort of morbidly obese adult patients. The cohort of 123 children and adolescents was also screened for MC4R mutations. This screening revealed four sequence variants (frequency ¼ 3.25%). Two children harbored the common Val103Ile polymorphism and two other patients contained the Ile251Leu polymorphism. Also in this cohort no pathogenic MC4R mutations were found.
In the adult and children cohort together, this adds up to a total frequency of MC4R sequence variants of 3.67%, including the three known polymorphisms (Val103Ile 2.3%; Thr112Met 0.46%; Ile251Leu 0.92%).
Discussion
Melanocortin-4 receptor deficiency is widely accepted as the most common form of monogenic obesity known so far. However, different studies reported varying frequencies of pathogenic MC4R mutations. An important factor that might influence the outcome of the study is the mode of selection and inclusion criteria used to recruit the patients. A number of groups detected mutations at high frequency among obese patients. [12] [13] [14] [15] [19] [20] [21] [22] [23] [24] As shown in Table 3 , the frequency of pathogenic MC4R mutations in these populations ranged from 2.5% 21 to as high as 6.3%. 12 These studies clearly focused on children with severe obesity and adults with reported early onset of obesity. However, when no selection for age of onset was made at the start of the study, pathogenic MC4R mutations were absent 9,10 or frequencies were low (0.5-2.1%). 18, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] However, the variation in the frequency of mutations can also be due to differences in ethnicity. There is a clear trend for higher frequencies in the British population, [20] [21] [22] while lower frequencies are observed in other populations, including Italians 26,31 and Germans. 32 Taken together these observations would suggest that pathogenic MC4R mutations may be a relatively frequent cause of severe early-onset obesity at least in some populations, but not of adult-onset obesity.
In the present study, we wanted to determine the frequency of pathogenic MC4R mutations in a Belgian obese population. Therefore, we screened 95 adult subjects and 123 children and adolescents with morbid obesity for MC4R sequence variants using the WAVE Nucleic Acid Fragment Analysis System (Transgenomic Inc., Crewe, UK). This method is highly sensitive and specific for mutation analysis. 16, 17 As mentioned earlier, the frequency of MC4R mutations varies according to the age of onset of obesity.
As our first cohort of morbidly obese adults are not selected for early age of onset, the absence of any mutation in 95 individuals is in line with previous reports. 9, 11, 34 These studies also did not select cases on the basis of age of onset and in none of these studies pathogenic MC4R mutations in morbidly obese adults were reported. Not finding a mutation in our cohort of 123 obese children and adolescents, on the other hand, was a bit more surprising since in all other studies that screened patients with early-onset obesity, pathogenic MC4R mutations were found, although the frequencies varied. When comparing MC4R analysis in Belgian obese children and adults S Beckers et al our cohort of children and adolescents to those of other groups, it becomes apparent that our cohort contains more adolescents. The mean age in our cohort is 16.5672.58 years and only three patients are in the prepubertal stage (o12 years), while for example Dubern et al. reported a mean age of 11.672.9 years. This difference in composition of the populations could explain why we find no pathogenic mutations. Our results would therefore suggest that MC4R mutations only might play a significant role in the etiology of obesity with onset before puberty. On the other hand, however, we must point out that although the DHPLC technology, used to screen MC4R in this study, has very high sensitivity and specificity, it is unlikely to be 100% in all instances. Therefore, it is possible that we might have missed some mutations although we must emphasize that this risk is very low. Mutation screening of MC4R did reveal three different sequence variants in our population. All three were previously reported: a G-A nucleotide change at position 307 resulting in the substitution of Val103 with Ile, 9 a C335T single nucleotide change which leads to a Thr112Met aminoacid substitution 18 and finally the Ile251Leu substitution resulting from the A751C nucleotide change. 19 In our study, the frequencies of the rare alleles of the latter two polymorphisms (Thr112Met 0.46%, Ile251Leu 0.92%) are in line with those reported previously. Based on metaanalysis of all studies listed in Table 4 , there is no significant difference between controls and cases for these two polymorphisms. 
Conclusion
In conclusion, in the present study no pathogenic MC4R mutations were found, even when a cohort of children and adolescents with early-onset obesity was screened. This suggests that MC4R mutations do not play a significant role in the etiology of obesity in the Belgian population, independent of the age of onset. The frequency of the Val103Ile polymorphism in our study is in line with other reports in cases supporting the suggested negative association between Ile103 allele and obesity. 34 Frequency ¼ individuals with polymorphism/total number screened (%). For Ref. 11 frequencies are given for a random population consisting of cases and controls.
MC4R analysis in Belgian obese children and adults S Beckers et al
